Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT03745547 |
Other study ID # |
SP/C/007 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
November 20, 2018 |
Est. completion date |
April 11, 2020 |
Study information
Verified date |
January 2021 |
Source |
Spire, Inc. |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The purpose of this study is to monitor adherence to a clothing-attached breathing monitor,
respiratory patterns, and activity levels in COPD patients, and correlate those respiratory
patterns and activity levels with patient-reported symptoms and events. To achieve this
purpose, Spire will collect data from a wearable monitor that participants attach to the
participant's clothing, an associated smartphone application, and completion of weekly
questions. The wearable monitor and the consumer smartphone application to be used are
consumer products and currently available in the market.
This study does not include clinical intervention and no doctors will be involved in this
study.
No clinical tests or office visits are included in this study. All data will be collected
through an online survey tool and remotely through the wearable sensors.
Description:
This is an exploratory, observational, non interventional, single-arm, open label, remote
pilot study involving up to 150 self-reported COPD participants. Eligible participants will
wear the Spire biophysiological health monitors for a period of 9 months while the
participants report symptoms on a weekly basis via brief surveys. If and when participants
incur a COPD-related exacerbation which results in a medication change after hospitalization
or contact with a healthcare provider, participants will report this on the weekly surveys.
When this survey is read by a study nurse, the nurse will follow up with the participant by
phone to conduct a post-exacerbation phone screening. This data would provide context to
inform how to correlate the biosensor-sensed physiological parameters with the exacerbation
self-reported data. All study participants will be remotely distributed throughout the United
States.